RU2166322C2 - Biopreparation for bee productivity enhancement - Google Patents

Abstract

FIELD: apiculture. SUBSTANCE: biopreparation has dry bacterial mass of bifidobacteria of the strain Bifidobacterium globosum VGNKI N BF- 4/DEP, dry bacterial mass of the strain of streptococci Streptococcus faecium VGNKI N 27/11-B-DEP as the source of biologically active substance. Biopreparation has ascorbic acid, carbohydrate, aluminium oxide, aluminium hydroxide and filling agent also. Biopreparation is diluted in small amount of boiled water and added to sugar syrup in the dose 1 g of preparation per 200 ml of sugar syrup and fed to bees twice. In the first feeding the preparation is given with the first additional feeding and in then in 7-10 days in the dose 100 ml of prepared syrup from preparation per one beehive in the second feeding. Preparation shows high growth-stimulating effect on bees and enhances their physiological activity. Invention can be used for production of biologically active probiotic addition for stimulation of physiological functions in bees. EFFECT: enhanced effectiveness of preparation, increased yield of commercial production. 3 cl, 1 tbl, 2 ex

Description

 The invention relates to the field of biotechnology and veterinary medicine and relates to the production of biological products, in particular biologically active probiotic additives to stimulate physiological functions in bees.

 There are various therapeutic and preventive additives for bees containing biologically active substances, for example, amino acids, yeast or blue-green algae chlorella (SU N 793556, 01/01/81; SU N 829088, 01/25/81; SU N 546337, 03/21/77).

 However, known additives do not contain a sufficient amount of proteins, vitamins, biologically active substances and therefore slightly affect the productivity of bees.

The closest analogue is a drug to stimulate the reproduction of bees and increase their resistance to various extreme factors, containing as a biologically active substance a mixture of ecdysterone and vitamin B ₁₂ and a filler is a mixture of sugar, starch and stearic acid (RU N 2034504, 05.10.95).

 The disadvantage of the closest analogue is that it mainly regulates the reproduction of bees and does not have a noticeable effect on such physiological functions of bees as the activity of summer and the production of mother milk and honey.

 One of the modern approaches to increasing the productivity of farm animals and poultry is the use of probiotics - preparations that include live microorganisms: representatives of the normal microflora of the intestinal tract or saprophytes that live in the external environment. Unlike antibiotics and other biologically active drugs, they are completely safe, environmentally friendly and have no contraindications for clinical use (Antipov V.A., Subbotin V.M. Effectiveness and prospects of using probiotics // Veterinary Medicine, 1980, N 12, p. 55-57).

 The mechanism of action of the drugs is based on the adhesive and antagonistic properties of probiotic bacteria, which displace conditionally pathogenic microorganisms from the intestinal population and non-specifically control their growth redundancy.

 It is known that in addition to its protective functions, intestinal normoflora takes an active part in the processes of microbial intestinal digestion, breaks down proteins to amino acids and peptides, produces acids, vitamins, bacteriocins and biologically active substances, and also stimulates the nonspecific resistance of the body.

 Probiotic preparations for normalizing intestinal biocenosis in bees have not been previously used, although antagonistic relationships between opportunistic and normal intestinal microflora in bees are likely to occur.

 The objective of the invention is the creation of an effective probiotic preparation to stimulate viability in bees and increase their productivity.

 The technical result of the invention is to obtain a probiotic preparation with active biological properties that can stimulate the viability of bees and to increase their productivity.

The essence of the invention is as follows: a biological product for increasing the productivity of bees contains as a biologically active substance a dry bacmid of bifidobacteria of the strain Bifidobacterium globosum VGNKI N BF-4 / DEP, a dry bakmass of a strain of streptococcus Streptococcus faecium VGNKI N 27/11-B-DE ascorbic acid, carbohydrates, aluminum oxide, aluminum hydroxide and filler, in the following ratio of components per 1 kg of the drug:
Dry bakmassa strain Bifidobacterium gtobosum VGNKI N BF-4 / DEPT with a content of 30-1000 billion microbial cells (mk) in 1 g - 2.0 - 4.0 g
Dry Bakmass of the strain Streptococcus faecium VGNKI N 27/11-B-DEPT with a content of 30-1000 billion m. in 1 g - 2.0 - 4.0 g
Carbohydrates - 20 - 40 g
Alumina - 10 - 30 g
Aluminum hydroxide - 100 - 300 g
Ascorbic acid - 100 - 300 g
Filler - Else
From carbohydrates, the biological product contains lactose or sucrose, and from fillers - food sugar.

 Strains of Bifidobacterium globosum VGNKI N BF-4 / DEPT and Streptococcus faecium VGNKI N 27/11-B-DEPT are known and include the composition of the drug Streptobifid, which is used to correct intestinal biocenosis in warm-blooded vertebrates and birds (RU N 2086248, publ. 08/10/97). However, it was unexpectedly discovered that known strains of bifidobacteria and streptococci in combination with ascorbic acid, taken in amounts according to the invention, were effective for stimulating physiological functions in bees.

 The strain of bifidobacteria Bifidobacterium globosum VGNKI N BF-4 / DEPT and the streptococcus strain Streptococcus faecium N 27/11-B-DEPT have high growth and biological activity in the bees, are capable of producing lactic acid and other biologically active substances. The synergy of the action of this combination is that streptococci, actively absorbing oxygen, improve the habitat for anaerobic bifidobacteria. Ascorbic acid, introduced into the composition of the drug, acts as an additional component for the binding of molecular oxygen and as a vitamin component.

 The biological product is diluted in a small amount of boiled water, added to sugar syrup at the rate of 1 g of the drug per 200 ml of sugar syrup and fed to bees twice: the first time with the first feeding and the second time after 7-10 days at the rate of 100 ml of the prepared syrup with the drug on one street.

 The invention is illustrated by the following examples.

 Example 1. A probiotic preparation is obtained by separate deep cultivation of strains of bifidobacteria, streptococci of liquid nutrient media adopted for the cultivation of these types of microorganisms.

 Strains of Streptococcus faecium VGNKI N 27/11 B-DEPT and bifidobacteria Bifidobacterium globosum VGNKI N BF-4 / DEPT are used.

 During the cultivation of bacteria for 16 + 2 hours, the biomass yield of each bacterial species is not less than 10 billion live microbial cells in 1 ml of culture suspension.

 The resulting cultures are concentrated 10-15 times depending on the density of the culture suspension, washed from metabolic products on separators or microfiltration plants.

 Concentrated bacterial suspensions are freeze-dried using conventional technology.

 The resulting dry semi-finished products of each strain contain at least 100 billion live microbial cells in one gram.

Next, the dry Bakmass of each strain is mixed in a 1: 1 ratio and carbohydrate, aluminum oxide and hydroxide, ascorbic acid and a filler (food sugar, powdered sugar) are added, in the following ratio of components per 1 kg:
Dry Bakmass of a streptococcus strain with a content of 10 - 3000 billion m. in 1 g - 3 g
Dry bakmassa strain of bifidobacteria with a content of 10-3000 billion m. in 1 g - 3 g
Carbohydrate (lactose or sucrose) - 30 g
Alumina - 20 g
Aluminum hydroxide - 200 g
Ascorbic acid - 200 g
Filler - Up to 1 kg
The specified composition allows you to get a series of the drug with a total CFU of streptococci and bifidobacteria (with an equal quantitative ratio) from 60 million to 6 billion m. and ascorbic acid up to 0.2 g per gram.

 Example 2. Obtained in example 1, the biological product is tested for biostimulating activity. Determine the biostimulating activity of the drug with a total concentration of bacteria of 60 million m. and 2 billion m. in one gram.

 As a biological model for testing the drug, bee colonies are used in weak apiaries that do not fulfill the plan for the delivery of marketable products per one bee family.

 The bee families in one apiary are divided into three groups - two experimental and one control with approximately the same number of streets in each hive (6-8 streets).

 A preparation with a concentration of microbial cells of 60 million and 2 billion in one gram is diluted in a small amount (20-50 ml) of boiled water and mixed with sugar syrup at the rate of 1 gram of the drug per 200 ml of sugar syrup and fed to the first and second experimental bee colonies groups respectively.

 The prepared syrup with the drug is given to the bees twice - the first time with the first feeding and the second time in 7-10 days, based on 100 ml of the prepared syrup with the drug per street.

 Bee colonies of the third group are used as a control: they receive sugar syrup without preparation as a top dressing.

 Accounting for the biological activity of the drug is carried out according to the activity of summer bees (number of flights per min), the number of brood grown in hundreds of cells per family and the yield of finished products as a percentage of the plan (the plan is 0.2 kg of royal jelly for one bee family and 10 kg marketable honey). The results are presented in the table.

 As can be seen from the table, the drug has a growth-stimulating effect on the body of bees, contributes to their physiological activity and the release of marketable products.

 The drug does not have a negative side effect on the body of bees and does not reduce the quality of marketable products, all honey samples from the bee colonies of the experimental groups met the requirements of GOST in terms of quality indicators.

Claims (2)

1. A biological product to increase the productivity of bees, containing a biologically active substance and an excipient, characterized in that it additionally contains ascorbic acid, carbohydrates, aluminum oxide, aluminum hydroxide, and as a biologically active substance it contains a dry bacillus of bifidobacteria of the strain Bifidobacterium globosum VGNKI BF-4 / DEPT, dry bacmass of a strain of streptococcus Streptococcus faecium VGNKI 27/11-B-DEPT in the following ratio of components per 1 kg of the drug:
Dry Bakmass of the strain Bifidobacterium globosum VGNKI BF-4 / DEPT with a content of 30 - 1000 billion m.k. in 1 g - 2.0 - 4.0 g
Dry Bakmass strain of Streptococcus faecium VGNKI 27/11-V-DEPT with a content of 30 - 1000 billion m.k. in 1g - 2.0 - 4.0 g
Carbohydrates - 20 - 40 g
Alumina - 10 - 30 g
Aluminum hydroxide - 100 - 300 g
Ascorbic acid - 100 - 300 g
Filler - Else
2. The drug according to claim 1, characterized in that it contains lactose or sucrose from carbohydrates.  3. The drug according to claim 1, characterized in that it contains food sugar as a filler.

Images